PharmaSGP Holding SE
XETRA:PSG
PharmaSGP Holding SE
Operating Income
PharmaSGP Holding SE
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Operating Income
€24.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Operating Income
-$122.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Operating Income
€2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Merck KGaA
XETRA:MRK
|
Operating Income
€3.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Operating Income
-€1.1m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Operating Income
€206.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
PharmaSGP Holding SE
Glance View
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. The company is headquartered in Graefelfing, Bayern. The company went IPO on 2020-06-19. The firm produces and develops non-chemical and over-the-counter drugs and other healthcare products.
See Also
What is PharmaSGP Holding SE's Operating Income?
Operating Income
24.6m
EUR
Based on the financial report for Dec 31, 2023, PharmaSGP Holding SE's Operating Income amounts to 24.6m EUR.
What is PharmaSGP Holding SE's Operating Income growth rate?
Operating Income CAGR 5Y
5%
Over the last year, the Operating Income growth was 39%. The average annual Operating Income growth rates for PharmaSGP Holding SE have been 19% over the past three years , 5% over the past five years .
You don't have any saved screeners yet